Muna Therapeutics ApS: Financial statements 2023
CVR: 41142871
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Muna Therapeutics ApS (CVR 41142871) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -110,624,445 and a net result of DKK -140,319,972 compared with DKK -127,682,346 the year before. Equity in the 2023 report amounted to DKK 126,959,857. The solvency ratio was 75.5%. The company had 18 employees in the financial year.
- Gross Profit
- DKK -110,624,445
- Profit/Loss
- DKK -140,319,972
- Equity
- DKK 126,959,857
- Total Assets
- DKK 168,210,488
- Employees
- 18
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -110.6 mio. | -140.3 mio. | 127 mio. | 18 |
| 2022 | - | -98.2 mio. | -127.7 mio. | 202 mio. | 16 |
| 2021 | - | -49.7 mio. | -61.5 mio. | 162.3 mio. | 7 |
| 2020 | - | -7.3 mio. | -7.4 mio. | 16.7 mio. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 27, 2023, Novo Holdings A/S is registered as an owner of Muna Therapeutics ApS with an ownership share of 15%.
As of November 15, 2023, Reza Halse has joined the board of directors of Muna Therapeutics ApS.
As of November 15, 2023, Luc Dochez has left the board of directors of Muna Therapeutics ApS.
Muna Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -98,234,040, and the net result was DKK -127,682,346.
About Muna Therapeutics ApS
Muna Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Michel Marcel A. Detheux. The board consists of Donald William Nicholson (chair), Camilla Petrycer Hansen, Cillian King and Eileen Elizabeth McGuire. The company's owners include Novo Holdings A/S, Sanofi Foreign Participations B.V. and Axxam S.p.A.. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -60,636,000 and a net result of DKK -125,695,000 compared with DKK -173,625,357 the year before. Equity in the 2025 report amounted to DKK -120,338,000.